NCT05325528

Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases

An Exploratory Study of Tislelizumab in Combination With Oxaliplatin and Tegafur for the Treatment of Gastric Cancer With Liver Metastases

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Liver metastases are one of the most common sites of metastasis in advanced gastric cancer. Chemotherapy remains the mainstay of treatment for these patients, but combination chemotherapy has encountered a bottleneck in improving patient survival, with no significant improvement in survival rates at 1, 3 or 5 years. In a previous phase II clinical study we not only observed the survival benefits of Tislelizumab in the treatment of GI tumors such as liver, oesophageal and some gastric cancers, but also confirmed the safety of Tislelizumab in the treatment of advanced GI tumors. This study is a clinical study of PD-1 monoclonal antibody (Tislelizumab) in combination with SOX (Tegafur + Oxaliplatin) for the treatment of liver metastases from gastric cancer. It aims to further explore a new combination therapy for liver metastases from gastric cancer, which is safe and effective for patients with difficult-to-treat disease.

Conditions

• Liver Metastases

Interventions

Type	Name	Description
DRUG	Tislelizumab in Combination with Oxaliplatin and Tegafur	6 cycles of Tislelizumab plus SOX regimen every 21 days

Timeline

• Start date: 2022-04-10
• Primary completion: 2025-08-31
• Completion: 2025-12-31
• First posted: 2022-04-13
• Last updated: 2023-02-01

Locations

1 site across 1 country: China